Conferences
ODYSSEY Demonstrates a Mortality Benefit in ACS Patients
Results of the much anticipated ODYSSEY Outcomes trial were presented today by Professor Phillipe Gabriel Steg, who is the chief of cardiology at Bichat-Claude Bernard Hospital, at the American College of Cardiology (ACC) Scientific Sessions in Orlando. Alirocumab, a monoclonal antibody directed against PCSK9, reduced major adverse cardiovascular events (MACE), myocardial infarction (MI), ischemic stroke and all-cause mortality in patients post-acute coronary syndrome (ACS), who were on high-intensity statin therapy. Continue reading
